AMEX · ASXC
Healthcare · Medical - Devices
$0.35
Up+$0.00 (+0.64%)
Updated Oct 7, 2026, 2:22 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ASXC
1M range · 0 trading sessions · Daily adjusted prices
ASXC does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning ASXC.
Company
Market Activity
Research & News
ASXC research
Company profile and research snapshot.
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 16, 2024 | HC Wainwright & Co. | Neutral | — |
| Apr 4, 2024 | HC Wainwright & Co. | Neutral | — |
| Mar 22, 2024 | HC Wainwright & Co. | Buy | — |
| Nov 16, 2023 | Cantor Fitzgerald | Neutral | — |
| Nov 15, 2023 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Aug 22, 2024
KARL STORZ, a leading medical technology company, has acquired Asensus Surgical, a global leader in innovative digital solutions for the operating room. The merger aims to accelerate the development and delivery of robotic and digital surgical solutions, benefiting patients and surgeons worldwide.
GlobeNewswire Inc. · Jul 24, 2024
Asensus Surgical, a leader in digital surgical solutions, announced that The Rocky Mountain Hospital for Children in Denver, Colorado has agreed to utilize the Senhance Surgical System, which is uniquely suited for pediatric surgery and aims to improve outcomes.
GlobeNewswire Inc. · Jul 23, 2024
Asensus Surgical has received FDA clearance to use its Senhance Surgical System for urological procedures in adult and pediatric patients in the US. The system's precision and digital capabilities make it well-suited for these procedures, offering surgeons benefits like smaller instruments and digital tools.
GlobeNewswire Inc. · Jul 16, 2024
Asensus Surgical, a medical device company, announced that LKH-Universitätsklinikum Graz in Austria has agreed to lease and utilize the Senhance Surgical System. This collaboration aims to expand the adoption of Asensus Surgical's innovative platform to benefit patients and healthcare providers.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ASXC.
No results
No recent SID articles mention ASXC.
